The FDA has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol (Teva Pharmaceucials, Jerusalem), a maintenance treatment option designed to eliminate the need for hand-breath coordination during inhalation.
Indications: QVAR RediHaler is a corticosteroid indication for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older.
Dosage and administration: Breath-actuated inhalation aerosol: 40 or 80 mcg per actuation.
Adverse reactions: The most common adverse reactions (incidence ≥3% and >placebo) include oral candidiasis, upper respiratory tract infection, nasopharyngitis, allergic rhinitis, oropharyngeal pain, and sinusitis.
Teva announces FDA approval of QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol. [news release]. Jerusalem; Teva Pharmaceutical Industrial Ltd.; August 7, 2017: http://www.tevapharm.com/news/teva_announces_fda_approval_of_qvar_redihaler_beclomethasone_dipropionate_hfa_inhalation_aerosol_08_17.aspx. Accessed August 12, 2017.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Steglatro for Adults with T2D, Pfizer news release; 2017 Dec 22
FDA Approves Ozempic for Treatment of T2D, Novo Nordisk news release; 2017 Dec 5
FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20
FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14
Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23